Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Non-interventional Study to Describe The Use of Maribavir and Its Effectiveness in Patients With Post-transplant Cytomegalovirus Infection/Disease in Line With Belgian Reimbursement Conditions (The MARIBEL Study)

NCT06677892 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT06677892
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06677892 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Non-interventional Study to Describe The Use of Maribavir and Its Effectiveness in Patients With Post-transplant Cytomegalovirus Infection/Disease in Line With Belgian Reimbursement Conditions (The MARIBEL Study)
Lead sponsor
Takeda
Phase
Observational
Overall status
Active, not recruiting
Start date
February 24, 2025
Completion date
September 30, 2026
Enrollment
66 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

cytomegalovirus (cmv)